Literature DB >> 20845106

TGF-β1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects.

Yongsheng Huang1, Binghui Li, Ji Qian, Jingtian Xie, Long Yu.   

Abstract

Transforming growth factor β1 (TGF-β1) is a cytokine, playing an important role in controlling cell proliferation and differentiation involved in breast cancer. It was reported the 29T/C polymorphism in TGF-β1 has been implicated in breast cancer risk. However, studies on the association between this polymorphism and breast cancer remain conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 10,341 cases and 15,655 controls from fifty published case-control studies was performed. Our analysis suggested that 29T/C has no association with a trend of breast cancer risk when using both dominant [odds ratio (OR) = 1.01, 95% confidence intervals (CI) 0.96-1.07] and recessive models (OR = 0.98, 95% CI 0.89-1.08) to analyze the data. In ethnic subgroups analysis, 29T/C also did not appear to be risk factors for breast cancer. However, larger scale primary studies are required to further evaluate the interaction of TGF-β1 29T/C polymorphism and breast cancer risk in specific populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20845106     DOI: 10.1007/s10549-010-0796-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians.

Authors:  Xiangyu Ma; Alicia Beeghly-Fadiel; Wei Lu; Jiajun Shi; Yong-Bing Xiang; Qiuyin Cai; Hongbing Shen; Chen-Yang Shen; Zefang Ren; Keitaro Matsuo; Ui Soon Khoo; Motoki Iwasaki; Jirong Long; Ben Zhang; Bu-Tian Ji; Ying Zheng; Wenjing Wang; Zhibin Hu; Yao Liu; Pei-Ei Wu; Ya-Lan Shieh; Shenming Wang; Xiaoming Xie; Hidemi Ito; Yoshio Kasuga; Kelvin Y K Chan; Hiroji Iwata; Shoichiro Tsugane; Yu-Tang Gao; Xiao Ou Shu; Harold L Moses; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-04-26       Impact factor: 4.254

2.  Association of TGFB1 29C/T and IL6 -572G/C polymorphisms with developmental hip dysplasia: a case-control study in adults with severe osteoarthritis.

Authors:  Tomislav Čengić; Vladimir Trkulja; Sandra Kraljević Pavelić; Ivana Ratkaj; Elitza Markova-Car; Michele Mikolaučić; Robert Kolundžić
Journal:  Int Orthop       Date:  2015-01-22       Impact factor: 3.075

3.  The L10P polymorphism and serum levels of transforming growth factor β1 in human breast cancer.

Authors:  Eva Taubenschuß; Erika Marton; Maurice Mogg; Barbara Frech; Lisa Ehart; Dana Muin; Martin Schreiber
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923

Review 4.  Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.

Authors:  Lijun Jing; Li Su; Brian Z Ring
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

5.  SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.

Authors:  Yongsheng Huang; Wenting Wu; Meng Nie; Chuang Li; Lin Wang
Journal:  Oncotarget       Date:  2016-11-15

6.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639

7.  Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study.

Authors:  Singh Pooja; Amirtharaj Francis; Singh Rajender; Rakesh Tamang; Raja Rajkumar; Karan Singh Saini; Kaling Megu; Madhu Mati Goel; Daminani Surekha; Digumarthi Raghunatha Rao; Lakshmi Rao; Lingadakai Ramachandra; Sandeep Kumar; Surender Kumar; Satti Vishnupriya; Kapaettu Satyamoorthy; Mahendra Pal Singh Negi; Kumarasamy Thangaraj; Rituraj Konwar
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.